LYT-100 in Healthy Volunteers and BCRL

  • STATUS
    Recruiting
  • participants needed
    82
  • sponsor
    PureTech
Updated on 19 February 2024
cancer
breast cancer
metastasis
cancer surgery
carcinoma
reconstructive surgery
lymphedema
secondary lymphedema
nipple reconstruction
adjuvant
HER2

Summary

Part 1 is a multiple ascending dose trial in healthy volunteers (HV) of LYT-100 to determine safety, tolerability, and pharmacokinetic (PK) profile under fed conditions.

Part 2 is a single dose safety, tolerability, and PK trial in HV of LYT-100 under fasted conditions.

Part 3 is a trial of up to 6-months duration for safety, tolerability, PK, biomarkers and exploratory clinical assessments in breast carcinoma patients with secondary lymphoedema

Description

Part 1: This is a randomised, double-blind, placebo-controlled, multiple ascending dose design to assess the safety, tolerability and PK profile of multiple doses of LYT-100 administered under fed conditions at steady state in healthy participants. Up to 4 dosing cohorts are planned.

Part 2: The dose level immediately below the maximally tolerated dose in Part 1 will be used in Part 2. Following a minimum 7-day washout of the cohort that received this dose, subjects in Part 2 will be administered a single dose of their assigned treatment under fasting conditions to permit a comparison of the rate and extent of absorption of LYT-100 under fasting conditions to the equivalent dose in a prior fed cohort.

Part 3: Once the optimal dose and regimen is determined with or without food, Part 3 will follow with an open-label, single treatment arm to assess the safety, tolerability, PK, biomarkers and effect on exploratory clinical endpoints of LYT-100 over a period of up to 6-months of dosing in breast carcinoma patients with secondary lymphoedema following sentinel lymph node biopsy and/or axillary node dissection, with or without radiation.

Details
Condition Lymphedema, Lymphedema, Breast Cancer Related Lymphoedema
Age 18years - 80years
Treatment Matching placebo, LYT-100
Clinical Study IdentifierNCT04243837
SponsorPureTech
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Part 1 and 2: Healthy Volunteers
Male or female between 18 and 75 years old (inclusive) at the time of screening
In good general health at screening, free from clinically significant unstable medical, surgical or psychiatric illness, at the discretion of the Investigator
Part 3: Patients with BRCL
Female or male between 18 and 80 years old (inclusive) at the time of informed consent
At least 6 months since any type of breast cancer surgery (excluding fine needle aspiration biopsy [FNA]), at the time of study screening. No intention to have breast reconstructive surgery, nipple reconstruction and/or tattooing during the course of the study
At least 3 months since completion of all types of treatment for breast cancer, including but not limited to neoadjuvant, radiotherapy, chemotherapy and immunotherapy, at the time of study screening
At least 3 months treatment of stable adjuvant treatment with hormonal or anti-HER2 therapy at the time of screening, with no planned changes to this therapy throughout the duration of the study
Diagnosis of primary breast cancer, and without evidence of recurrence of breast cancer and/or metastasis for at least 6 months since breast cancer surgery, as determined at screening and baseline
Documented evidence of Stage 1 or 2 lymphoedema
Receiving standard of care compression or agreeable to using care compression, or no compression at all 4 weeks prior to screening and throughout the study

Exclusion Criteria

Part 1 and 2: Healthy Volunteers
History or presence of malignancy at screening or baseline, with the exception of adequately treated localised skin cancer (basal cell or squamous cell carcinoma) or carcinoma in-situ of the cervix
Clinically significant infection within 28 days of the start of dosing, or infections requiring parenteral antibiotics within the 6 months prior to screening
Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs within 3 months prior to study drug administration; corticosteroids are permitted at the discretion of the Investigator)
History or presence at screening or baseline of a condition associated with significant immunosuppression
Part 3: Patients with BRCL
Bilateral lymphoedema or history of bilateral axillary lymph node removal (i.e., sentinel lymph node or axillary lymph node dissection), or primary lymphoedema or lymphatic or vascular malformation, determined at screening
Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs within 3 months prior to study drug administration; corticosteroids are permitted at the discretion of the PI
Recent history (in the 8 weeks prior to screening) of cellulitis, lymphangitis, dermatitis, necrotising fasciitis, or current open wounds or sores in the affected extremity
Stage III lymphoedema, or history of clinically diagnosed secondary lymphoedema greater than 2 years, determined at screening
Initiated use of compression or manual lymphatic drainage or other lymphoedema therapies at the start of the study within 4 weeks of the screening visit. Rescreening is allowed following a course of stable compression regimen of > 4 weeks
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 â€¢ 

Private

Reply by • • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.